Abstract
Background. Glioblastoma multiforme, commonly known as GBM or glioblastoma is a grade IV astrocytoma. Brain tumors are difficult to treat and lead to poor prognosis and survival in patients. Gliomas are categorized into four different grades among which GBM is the worst grade primary brain tumor with a survival of less than a year. The genomic heterogeneity of the brain tumor results in different profiles for patients diagnosed with glioblastoma. Precision medicine focuses on this specific tumor type and suggests specialized treatment for better prognosis and overall survival (OS). Purpose. With the recent advancements in Genome-Wide Studies (GWS) and various characterizations of brain tumors based on genetic, transcriptomic, proteomic, epigenetic, and metabolomics, this review discusses the advancements and opportunities of precision medicine therapeutics, drugs, and diagnosis methods based on the different profiles of glioblastoma. Methods. This review has exhaustively surveyed several pieces of works from various literature databases. Conclusion. It is evident that most primary brain tumors including glioblastoma require specific and precision therapeutics for better prognosis and OS. In present and future, molecular understanding and discovering specific therapies are essential for treatment in the field of neurooncology.
Recommended Citation
Iyer, Karan; Saini, Shubham; Bhadra, Suman; Kulavi, Sohini; and Bandyopadhyay, Jaya
(2023)
"Precision Medicine Advancements in Glioblastoma: A Systematic Review,"
BioMedicine: Vol. 13
:
Iss.
2
, Article 1.
DOI: 10.37796/2211-8039.1403
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
